Your browser doesn't support javascript.
loading
New-onset aortitis manifesting as relapsing giant cell arteritis successfully managed with tocilizumab monotherapy. A comment on: Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients. by Calderon-Goerc.
Guarda, Max; Araoz, Philip A; Ghaffar, Umar; Warrington, Kenneth J; Koster, Matthew J.
Affiliation
  • Guarda M; Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
  • Araoz PA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Ghaffar U; Department of Internal Medicine, Division ofnRheumatology, Mayo Clinic, Rochester, MN, USA.
  • Warrington KJ; Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
  • Koster MJ; Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA. koster.matthew@mayo.edu.
Clin Exp Rheumatol ; 41(4): 989-990, 2023 04.
Article in En | MEDLINE | ID: mdl-36995327
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aortitis / Giant Cell Arteritis Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Exp Rheumatol Year: 2023 Document type: Article Affiliation country: United States Country of publication: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aortitis / Giant Cell Arteritis Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Exp Rheumatol Year: 2023 Document type: Article Affiliation country: United States Country of publication: Italy